A PHASE 3, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, PARALLEL-GROUP,
MULTICENTER TRIAL TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF
SUBCUTANEOUS TEPROTUMUMAB IN PARTICIPANTS WITH MODERATE-TO-SEVERE ACTIVE
THYROID EYE DISEASE
- Registry ID
- HZNP-TEP-305
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- AMGEN CANADA INC
- Start date
- 2025-02-20
- Last update
- 2024-06-26
Conditions
Related clinical trials
- A PHASE 1/2, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTICENTER
STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF AMG 732 IN
HEALTHY SUBJECTS AND SUBJECTS WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE
DISEASE
- A PHASE 3, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF EFGARTIGIMOD PH20 SC ADMINISTERED BY PREFILLED SYRINGE IN ADULT PARTICIPANTS WITH THYROID EYE DISEASE
- A MULTICENTER PHASE 2B RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED DOSE-RANGING STUDY OF TOUR006 IN PARTICIPANTS WITH THYROID EYE DISEASE
- A PHASE III, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTICENTER
STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND
PHARMACODYNAMICS OF SATRALIZUMAB IN PARTICIPANTS WITH MODERATE-TO-SEVERE
THYROID EYE DISEASE
- A PHASE 2B, RANDOMIZED, DOUBLE-MASK, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF LINSITINIB IN SUBJECTS WITH ACTIVE, MODERATE TO SEVERE THYROID EYE DISEASE (TED)
- A MULTIPLE ASCENDING DOSE (MAD) SAFETY, TOLERABILITY AND EFFICACY STUDY OF VRDN-001, A HUMANIZED MONOCLONAL ANTIBODY DIRECTED AGAINST THE IGF-1 RECEPTOR, IN NORMAL HEALTHY VOLUNTEERS (NHVS) AND SUBJECTS WITH THYROID EYE DISEASE (TED)
View on source registry